{"id":"NCT01919697","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)","officialTitle":"An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation (CIC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2016-01","completion":"2016-03","firstPosted":"2013-08-09","resultsPosted":"2019-07-02","lastUpdate":"2019-07-02"},"enrollment":2370,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Plecanatide","otherNames":[]}],"arms":[{"label":"Plecanatide 3.0 mg","type":"EXPERIMENTAL"},{"label":"Plecanatide 6.0 mg","type":"EXPERIMENTAL"}],"summary":"This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).","primaryOutcome":{"measure":"Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)","timeFrame":"From first dose up to 72 weeks","effectByArm":[{"arm":"Plecanatide 3 mg","deltaMin":123,"sd":null},{"arm":"Plecantide 6 mg","deltaMin":620,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":220,"countries":["United States","Canada"]},"refs":{"pmids":["29343131"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":224},"commonTop":["Diarrhoea","Urinary tract infection"]}}